HR and breast carcinoma: In summary, our study revealed the stimulatory effects of XBP1s on cell proliferation, cell cycle progression from G1 to S phase, and the development of cross‐resistance to palbociclib and fulvestrant by modulating the SND1/E2F1 axis in HR+/HER2− breast cancer.